The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells

被引：9

作者：

Schwarz, Kerstin ^{[1
]}

Romanski, Annette ^{[1
]}

Puccetti, Elena ^{[2
]}

Wietbrauk, Sarah ^{[1
]}

Vogel, Anja ^{[1
]}

Keller, Maren ^{[1
]}

Scott, Jeffrey W. ^{[3
]}

Serve, Hubert ^{[1
]}

Bug, Gesine ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Dept Med Hematol & Oncol 2, Frankfurt, Germany

[2] Univ Marburg, Inst Mol Biol & Tumour Res, Marburg, Germany

[3] Novartis Pharmaceut, Florham Pk, NJ USA

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 01期

关键词：

Deacetylase inhibitor; Acute myeloid leukaemia; CD34(+) progenitor cells; Notch signalling; TRANS-RETINOIC ACID; VALPROIC ACID; SELF-RENEWAL; DIFFERENTIATION; LEUKEMIA; EXPRESSION; PROLIFERATION; MAINTAINS; COMPLEX; ETO;

D O I：

10.1016/j.leukres.2010.06.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML progenitor cells (AML-PC) undergo significant apoptosis in response to the deacetylase inhibitor (DACi) LAQ824 and lose the replating capacity which was not observed with the DACi valproic acid. Treatment of normal hematopoietic progenitor cells (HPC) with LAQ824 resulted in (i) inhibition of differentiation, (ii) an G2/M cell cycle arrest exclusively in multipotent CD34(+) HPC and (iii) induction of apoptosis predominantly in committed CD34(-) HPC. Gene expression analysis showed induction of coactivator and target genes of the notch pathway as well as cell cycle arrest-inducing genes in the most primitive CD34(+) CD38(-) HPC population which may in part be responsible for the considerable, but reversible haematotoxicity of this drug. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：119 / 125

页数：7

共 50 条

[21] A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors
Rowinsky, EK
Pacey, S
Patnaik, A
O'Donnell, A
Mita, MM
Atadja, P
Peng, B
Dugan, M
Scott, JW
De Bono, JS
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 200S - 200S
[22] Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies
Rowinsky, EK
de Bono, J
Deangelo, DJ
van Oosterom, A
Morganroth, J
Laird, GH
Dugan, M
Scott, JW
Ottmann, OG
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 224S - 224S
[23] Preclinical evaluation of the effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise, Annie
Momparler, Richard L.
CANCER RESEARCH, 2006, 66 (08)
[24] Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824
Atadja, P
Gao, L
Kwon, P
Trogani, N
Walker, H
Hsu, M
Yeleswarapu, L
Chandramouli, N
Perez, L
Versace, R
Wu, A
Sambucetti, L
Lassota, P
Cohen, D
Bair, K
Wood, A
Remiszewski, S
CANCER RESEARCH, 2004, 64 (02) : 689 - 695
[25] LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma:: Results of a pre-clinical evaluation in vitro and in vivo.
Catley, L
Weisberg, E
Tai, YT
Lin, B
Mitsiades, N
Hideshima, T
LeBlanc, R
Shringapure, R
Burger, R
Mitsiades, C
Chauhan, D
Schlossman, R
Munshi, N
Richardson, P
Griffin, J
Anderson, K
BLOOD, 2002, 100 (11) : 106A - 106A
[26] Selective induction of mitochondrial cell death pathway by LAQ 824, a histone deacetylase inhibitor
Wang, Shaowen
Yan-Neale, Yan
Cai, Richard
Cohen, Dalia
CANCER RESEARCH, 2006, 66 (08)
[27] Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3
Bali, P
George, P
Cohen, P
Tao, JG
Guo, F
Sigua, C
Vishvanath, A
Scuto, A
Annavarapu, S
Fiskus, W
Moscinski, L
Atadja, P
Bhalla, K
CLINICAL CANCER RESEARCH, 2004, 10 (15) : 4991 - 4997
[28] Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells
Nimmanapalli, R
Fuino, L
Bali, P
Gasparetto, M
Glozak, M
Tao, JG
Moscinski, L
Smith, C
Wu, J
Jove, R
Atadja, P
Bhalla, K
CANCER RESEARCH, 2003, 63 (16) : 5126 - 5135
[29] The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Grant, S
LEUKEMIA, 2004, 18 (12) : 1931 - 1933
[30] The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
S Grant
Leukemia, 2004, 18 : 1931 - 1933

← 1 2 3 4 5 →